Imunon, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $7,780,698 | $11,639,411 |
| General and administrative | 6,869,996 | 7,493,035 |
| Total operating expenses | 14,650,694 | 19,132,446 |
| Loss from operations | (14,650,694) | (19,132,446) |
| Other income: | ||
| Investment income, net | 155,666 | 512,204 |
| Total other income, net | 155,666 | 512,204 |
| Net loss | $(14,495,028) | $(18,620,242) |
| Net loss per common share - basic and diluted | $(6.83) | $(16.94) |
| Weighted average common shares outstanding - basic and diluted | 2,123,344 | 1,098,899 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.